Epigral Limited Appoints Priyanka Agarwal Chopra as Independent Director; Nirali Bhavin Parikh Completes Tenure

Mumbai, February 28, 2025: Epigral Limited (NSE: EPIGRAL, BSE: 543332), formerly known as Meghmani Finechem Limited, announced key changes in its board of directors today, including the appointment of Priyanka Agarwal Chopra as a Non-Executive Independent Woman Director and the cessation of Nirali Bhavin Parikh’s directorship following the completion of her tenure.

Key Corporate Announcements​

The Board of Directors at Epigral Limited, through a circular resolution dated February 28, 2025, approved the following:

1. Appointment of Priyanka Agarwal Chopra:
   Ms. Priyanka Agarwal Chopra (DIN: 10011547) has been appointed as an Additional Director, assuming the role of Non-Executive Independent Woman Director for a term of five years effective from February 28, 2025. Her appointment is subject to shareholder approval. Ms. Chopra will not be liable to retire by rotation.
   
   Professional Background:
   Ms. Chopra brings extensive experience spanning over 12 years in early-stage investment and venture capital. She is currently serving as CEO and Managing Partner at IIMA Ventures (formerly IIMA-CIIE), as well as Venture Partner at Bharat Innovation Fund. Her notable tenure includes roles at Sun Microsystems, IBM, and Piramal Sarvajal, highlighting her expertise in technology-driven strategic roles and social impact initiatives.
   
   She holds an MBA from The Wharton School (University of Pennsylvania) and an M.S. in Electrical Engineering from the Georgia Institute of Technology.
2. Completion of Nirali Bhavin Parikh's Tenure:
   Ms. Nirali Bhavin Parikh (DIN: 05309425) ceased to be an Independent Director effective from the close of business hours on February 28, 2025, following the completion of her second consecutive five-year term. The board expressed appreciation for her significant contributions to the company's governance during her tenure.

Management Commentary​

The company stated,

“The Board places on record their sincere appreciation for the contributions made by Ms. Nirali Bhavin Parikh during her association with Epigral Limited.”

Click to expand...

Ms. Chopra's appointment aligns with the company's strategic focus on bolstering corporate governance and bringing diverse perspectives to its leadership team.

Compliance and Regulatory Disclosure​

The company confirmed Ms. Chopra fulfills the independence criteria set forth under the Companies Act, 2013, and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Further, Ms. Chopra is not related to any existing directors of the company, nor is she debarred from holding directorship by SEBI or any other regulatory authority.

These changes were announced in compliance with Regulation 30 of SEBI Listing Regulations and communicated to the BSE and NSE.

Strategic Outlook & Market Positioning​

Epigral Limited continues to strengthen its governance framework through the strategic appointment of experienced industry leaders. The addition of Ms. Chopra is expected to positively impact the company’s strategic direction, particularly in areas involving innovation, technology, and startup ecosystems, further enhancing shareholder value.